Johnson & Johnson(JNJ) - Stock detail

Johnson & Johnson

US
JNJ
Johnson & Johnson(Listing date: 09/25/1944)

Johnson & Johnson was incorporated in New Jersey in 1887. Johnson & Johnson and its subsidiaries are engaged in the research and development, manufacturing and sale of various products in the healthcare field. Johnson & Johnson is a holding company, with its operating companies located in nearly all countries around the world. The company's primary focus is on products related to human health and well-being. The company is divided into two business segments: Innovative Medicine and MedTech.

AI Debate JudgeBuy
Generated at:2026-04-18 05:46:30
Data source: real-time quotes, news and fundamental analysis, analysis date: 2026-04-17
  • Most importantly, the bullish case is grounded in concrete, recent, and high-impact data, including a strong Q1 beat.
  • Furthermore, the board's approval of a 64th consecutive dividend increase signals deep confidence in cash flow.
  • Moreover, a major analyst (Barclays) raised its price target to $255 based on 'Strong Pharma Momentum' after the results.
  • In addition, the current price appears undervalued relative to a fundamental fair value range of $240-$250.
  • Therefore, the bullish view is an opportunity assessment backed by new data, while the bearish view is a reactive risk assessment.
Bear Case
  • Technical picture is weak, with the stock in a downtrend below all moving averages.
  • The Stelara patent cliff poses a serious, multi-year headwind for revenue.
  • Overhead supply from underwater holders creates significant technical resistance.
  • Recent price action reflects negative market sentiment and known challenges.
Bull Case
  • Strong Q1 results beat expectations, showing growth drivers like Darzalex are working.
  • Unmatched 64th consecutive dividend increase demonstrates robust financial health.
  • Analyst price target raised to $255 post-earnings on 'Strong Pharma Momentum'.
  • Company framed as a 'growth machine' with clear $100B revenue target for 2026.
  • Current stock price is undervalued relative to fundamental fair value of $240-$250.
  • Technical weakness presents a short-term buying opportunity amid strong fundamentals.

Price Targets

Analysis Summary

Target Price Analysis: We’ll synthesize the reports into a risk-adjusted framework.

  • Conservative Scenario (1 Month): The technical resistance at the moving average cluster (~$238-$240) and overhead supply caps the initial bounce. Positive news flow prevents a new low. Target: $240.
  • Baseline Scenario (3 Months): The fundamental fair value ($240-$250) and the positive news momentum prevail. The stock recovers to trade within its pre-earnings range, aiming for the Barclays target. Target: $250.
  • Optimistic Scenario (6 Months): JNJ demonstrates continued execution, quelling Stelara fears. The “growth machine” narrative gains traction, driving a re-rating. The stock challenges and exceeds the Barclays target. Target: $260.

3. Comprehensive Target Price Range:

  • 1-Month Target: $238 - $242 (Overcome immediate technical resistance)
  • 3-Month Target: $248 - $255 (Achieve fundamental fair value & hit analyst target)
  • 6-Month Target: $255 - $265 (Momentum-driven expansion on confirmed growth trajectory)

Specific Price Targets: $240 (1M), $252 (3M), $260 (6M).

Action Strategy

Strategy Summary

Detailed Investment Plan for the Trader

1. Strategic Actions:

  • Entry: Initiate a long position. Given the technical weakness, employ a scaled entry strategy. Allocate 50% of the intended capital now (~$234). Place the remaining 50% to be deployed on a daily close above the 10-day EMA (~$238) or on a pullback to test the strong support at $230, whichever comes first. This respects the technical risk while ensuring participation on a confirmed rebound.
  • Stop-Loss: A definitive technical break would invalidate the fundamental thesis. Place a hard stop-loss at $229.90, just below the major support zone of $230 and the recent low. This limits downside risk to approximately 1.8% from the initial entry.
  • Time Horizon: This is a 3-6 month tactical investment aligned with the market digesting Q1 results and the new analyst targets, with a long-term hold component due to the dividend growth story.
AI Bull vs AI Bear
Round-by-round arguments

Round 1 - Bear case

  • The Bearish Analyst disputes the bullish narrative. The dividend increase is overshadowed by JNJ's technical breakdown, trading below all key moving averages with negative momentum. The critical threat is the Stelara biosimilar revenue cliff, a multi-billion dollar hole. The recent margin surge is deemed anomalous, and the current P/E is considered full given pending challenges. With over 92% of holders underwater, creating a heavy resistance ceiling near $238, the risk/reward is poor, favoring a further decline toward $225.

Detail Preview

Alright, let's cut through the optimism. I’ve reviewed the bullish case, and while it sounds compelling on the surface, it’s built on a foundation of selective reading, ignoring glaring technical decay, and dismissing serious fundamental headwinds. The narrative is positive, but the data tells a different story. Let me engage directly with the bullish analyst’s points. First, on the "strong Q1 results and dividend hi…

Round 2 - Bear case

  • The analyst argues J&J's future revenue targets do not concretely address the imminent "cliff" from Stelara's biosimilar erosion. Strong Q1 results are deemed anomalous and not a sustainable growth base. Technically, the stock is in a confirmed downtrend with overwhelming overhead supply from underwater holders. The dividend commitment strains capital allocation given high debt, and the current P/E is full despite the looming patent cliff. The bullish case relies on misplaced optimism over future pipelines and already-priced-in momentum.

Detail Preview

Alright, let's address this point by point. While my bullish colleague paints a compelling picture of strategic execution and long-term promises, I believe the current reality for J&J is far riskier and the optimism is severely misplaced. Let me explain why. First, the bullish argument hinges on "executing a multi-year plan." This is a classic case of management selling a future story to distract from present headwin…

Round 1 - Bull case

  • J&J is executing a multi-year plan to overcome the Stelara loss, targeting $100B in 2026 revenue after a strong Q1. Growth is driven by Innovative Medicine and MedTech, with a path to double-digit growth by 2030 from new blockbusters. Its competitive moat includes 64 years of dividend growth and defensive durability. Analysts like Barclays see strong momentum, raising the target to $255. The current valuation is seen as reasonable, with the pullback presenting an opportunity based on long-term fundamentals, not short-term technicals.

Detail Preview

Excellent. Let's address this point by point. My bullish colleague is focused on a short-term, static technical picture and a single known headwind, while ignoring the powerful, multi-year fundamental transformation underway and the compelling valuation opportunity this recent pullback presents. Growth Potential: Not Just a Hope, a Plan in Execution First, on growth. My bearish friend calls the Stelara loss a "cliff.…

Round 2 - Bull case

  • The Q1 revenue beat validates that growth engines in Innovative Medicine (Darzalex, Carvykti) and MedTech are already offsetting the known Stelara loss. JNJ's deep pipeline supports its 2030 targets. The current oversold technical condition is a setup for a rebound, with analyst upgrades (e.g., Barclays $255 target) and a 64th dividend hike poised to shift sentiment. The P/E of ~27 is justified for a Dividend King with this moat and momentum. Debt is managed by strong cash flow, as shown by $5.24B Q1 net income. The company is a resilient, dual-engine growth machine.

Detail Preview

Excellent. Let's get straight to the point. My bearish colleague is fixated on a rearview mirror technical chart and a single, well-telegraphed headwind, completely missing the forest for a single, strategically managed tree. The case for Johnson & Johnson is not about avoiding a challenge; it's about how a premier global enterprise is navigating through it and emerging stronger. Let's break this down. Refuting the B…

Round 1 - Bear case

  • The Bearish Analyst disputes the bullish narrative. The dividend increase is overshadowed by JNJ's technical breakdown, trading below all key moving averages with negative momentum. The critical threat is the Stelara biosimilar revenue cliff, a multi-billion dollar hole. The recent margin surge is deemed anomalous, and the current P/E is considered full given pending challenges. With over 92% of holders underwater, creating a heavy resistance ceiling near $238, the risk/reward is poor, favoring a further decline toward $225.

Detail Preview

Alright, let's cut through the optimism. I’ve reviewed the bullish case, and while it sounds compelling on the surface, it’s built on a foundation of selective reading, ignoring glaring technical decay, and dismissing serious fundamental headwinds. The narrative is positive, but the data tells a different story. Let me engage directly with the bullish analyst’s points. First, on the "strong Q1 results and dividend hi…

Round 1 - Bull case

  • J&J is executing a multi-year plan to overcome the Stelara loss, targeting $100B in 2026 revenue after a strong Q1. Growth is driven by Innovative Medicine and MedTech, with a path to double-digit growth by 2030 from new blockbusters. Its competitive moat includes 64 years of dividend growth and defensive durability. Analysts like Barclays see strong momentum, raising the target to $255. The current valuation is seen as reasonable, with the pullback presenting an opportunity based on long-term fundamentals, not short-term technicals.

Detail Preview

Excellent. Let's address this point by point. My bullish colleague is focused on a short-term, static technical picture and a single known headwind, while ignoring the powerful, multi-year fundamental transformation underway and the compelling valuation opportunity this recent pullback presents. Growth Potential: Not Just a Hope, a Plan in Execution First, on growth. My bearish friend calls the Stelara loss a "cliff.…

Round 2 - Bear case

  • The analyst argues J&J's future revenue targets do not concretely address the imminent "cliff" from Stelara's biosimilar erosion. Strong Q1 results are deemed anomalous and not a sustainable growth base. Technically, the stock is in a confirmed downtrend with overwhelming overhead supply from underwater holders. The dividend commitment strains capital allocation given high debt, and the current P/E is full despite the looming patent cliff. The bullish case relies on misplaced optimism over future pipelines and already-priced-in momentum.

Detail Preview

Alright, let's address this point by point. While my bullish colleague paints a compelling picture of strategic execution and long-term promises, I believe the current reality for J&J is far riskier and the optimism is severely misplaced. Let me explain why. First, the bullish argument hinges on "executing a multi-year plan." This is a classic case of management selling a future story to distract from present headwin…

Round 2 - Bull case

  • The Q1 revenue beat validates that growth engines in Innovative Medicine (Darzalex, Carvykti) and MedTech are already offsetting the known Stelara loss. JNJ's deep pipeline supports its 2030 targets. The current oversold technical condition is a setup for a rebound, with analyst upgrades (e.g., Barclays $255 target) and a 64th dividend hike poised to shift sentiment. The P/E of ~27 is justified for a Dividend King with this moat and momentum. Debt is managed by strong cash flow, as shown by $5.24B Q1 net income. The company is a resilient, dual-engine growth machine.

Detail Preview

Excellent. Let's get straight to the point. My bearish colleague is fixated on a rearview mirror technical chart and a single, well-telegraphed headwind, completely missing the forest for a single, strategically managed tree. The case for Johnson & Johnson is not about avoiding a challenge; it's about how a premier global enterprise is navigating through it and emerging stronger. Let's break this down. Refuting the B…

End of debate